Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease—The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study
MetadataShow full item record
© 2017 The Authors. Catheterization and Cardiovascular Interventions Published by Wiley Periodicals, Inc. Objectives: The purpose of this study was to assess the safety and performance of Stellarex Drug-coated balloon (DCB). Background: DCB coatings differ in excipients, paclitaxel dose, and coating morphologies. Due to these differences, a class effect with DCBs has not been demonstrated. Consequently, each DCB needs to be evaluated independently based on its own clinical study results. Methods: The ILLUMENATE Global Study is a prospective, multicenter, single-arm study. Patients with intermittent claudication or ischemic rest pain due to superficial femoral artery (SFA) and/or popliteal peripheral artery disease (PAD) were treated with the Stellarex DCB. The primary efficacy endpoint was primary patency, defined as freedom from restenosis with peak systolic velocity ratio =2.5 or clinically-driven target lesion revascularization (CD-TLR) at 12 months. The primary safety endpoint was freedom from device and procedure-related death through 30 days postprocedure and freedom from target limb major amputation and CD-TLR through 12 months. Results: In total, 417 lesions were treated in 371 patients. The mean lesion length was 7.5 ± 5.3 cm, 40.8% of lesions were severely calcified per core laboratory fluoroscopy criteria and 31.3% were total occlusions. Primary patency by independent duplex core lab evaluation was 81.4% and the freedom from CD-TLR was 94.8% day 365 per Kaplan-Meier estimate. The majority of patients experienced improvements in their Rutherford classification (90.3%) and walking impairment questionnaire score (83.6%) at 12 months compared to baseline. Conclusions: This study validated previous positive findings and confirms the strong safety profile and effectiveness outcomes.
Showing items related by title, author, creator and subject.
Utility of the ACC/AHA lesion classification as a predictor of procedural, 30-day and 12-month outcomes in the contemporary percutaneous coronary intervention era.Theuerle, J.; Yudi, M.; Farouque, O.; Andrianopoulos, N.; Scott, P.; Ajani, A.; Brennan, Angela; Duffy, S.; Reid, Christopher; Clark, D.; Melbourne Interventional Group. (2017)BACKGROUND: Correlations between the ACC/AHA coronary lesion classification and clinical outcomes in the contemporary percutaneous coronary intervention (PCI) era are not well established. METHODS: We analyzed clinical ...
Recent trends in Australian percutaneous coronary intervention practice: Insights from the melbourne interventional group registryYan, B.; Ajani, A.; Clark, D.; Duffy, S.; Andrianopoulos, N.; Brennan, A.; Loane, P.; Reid, Christopher (2011)Objective: To evaluate percutaneous coronary intervention (PCI) practice trends and 12-month outcomes in Australia in the era of drug-eluting stents (DES). Design, setting and patients: Prospective study of consecutive ...
Quantitative comparison of cortical and deep grey matter in pathological subtypes of unilateral cerebral palsyScheck, S.; Pannek, K.; Fiori, S.; Boyd, Roslyn; Rose, S. (2014)© 2014 Mac Keith Press. Aim: The aim of this study was to quantify grey matter changes in children with unilateral cerebral palsy (UCP), differentiating between cortical or deep grey matter (CDGM) lesions, periventricular ...